Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
RYCEF
-0.3000
The China Mail - Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
USD
-
AED 3.672502
AFN 66.402915
ALL 83.761965
AMD 382.479948
ANG 1.789982
AOA 917.000201
ARS 1450.762623
AUD 1.544903
AWG 1.805
AZN 1.701421
BAM 1.695014
BBD 2.010894
BDT 121.852399
BGN 1.694604
BHD 0.376964
BIF 2945.49189
BMD 1
BND 1.302665
BOB 6.907594
BRL 5.350298
BSD 0.998384
BTN 88.558647
BWP 13.433114
BYN 3.402651
BYR 19600
BZD 2.007947
CAD 1.412445
CDF 2149.99973
CHF 0.80729
CLF 0.024051
CLP 943.5053
CNY 7.11935
CNH 7.12591
COP 3784.2
CRC 501.791804
CUC 1
CUP 26.5
CVE 95.850071
CZK 21.099704
DJF 177.785096
DKK 6.47216
DOP 64.236284
DZD 130.473892
EGP 47.294756
ERN 15
ETB 153.291763
EUR 0.86677
FJD 2.28685
FKP 0.766404
GBP 0.76225
GEL 2.705007
GGP 0.766404
GHS 10.944975
GIP 0.766404
GMD 73.000027
GNF 8666.525113
GTQ 7.6608
GYD 209.15339
HKD 7.77501
HNL 26.251771
HRK 6.529199
HTG 130.6554
HUF 334.857498
IDR 16710
ILS 3.266415
IMP 0.766404
INR 88.63245
IQD 1307.95197
IRR 42112.495602
ISK 126.719609
JEP 0.766404
JMD 160.148718
JOD 0.70899
JPY 153.162497
KES 128.989835
KGS 87.450154
KHR 4007.27966
KMF 421.000135
KPW 900.033283
KRW 1455.925043
KWD 0.30695
KYD 0.832073
KZT 525.442751
LAK 21688.845749
LBP 89406.213032
LKR 304.463694
LRD 182.946302
LSL 17.350557
LTL 2.95274
LVL 0.60489
LYD 5.459044
MAD 9.311066
MDL 17.092121
MGA 4502.259796
MKD 53.325591
MMK 2099.044592
MNT 3585.031206
MOP 7.994609
MRU 39.945401
MUR 45.949817
MVR 15.40501
MWK 1731.225057
MXN 18.582475
MYR 4.174987
MZN 63.959675
NAD 17.350557
NGN 1435.980294
NIO 36.7374
NOK 10.21145
NPR 141.508755
NZD 1.778663
OMR 0.384504
PAB 0.999779
PEN 3.371567
PGK 4.273464
PHP 59.108498
PKR 282.311102
PLN 3.683998
PYG 7072.751145
QAR 3.643566
RON 4.408202
RSD 101.591989
RUB 81.24968
RWF 1450.689639
SAR 3.75059
SBD 8.230592
SCR 14.004029
SDG 600.499624
SEK 9.58305
SGD 1.305145
SHP 0.750259
SLE 23.196236
SLL 20969.499529
SOS 570.604013
SRD 38.503502
STD 20697.981008
STN 21.232987
SVC 8.735857
SYP 11056.895466
SZL 17.336517
THB 32.401501
TJS 9.227278
TMT 3.5
TND 2.959939
TOP 2.342104
TRY 42.197505
TTD 6.76509
TWD 30.985799
TZS 2460.000261
UAH 42.011587
UGX 3491.096532
UYU 39.813947
UZS 11951.241707
VES 227.27225
VND 26310
VUV 122.169446
WST 2.82328
XAF 568.486781
XAG 0.020726
XAU 0.000251
XCD 2.70255
XCG 1.799344
XDR 0.707015
XOF 568.486781
XPF 103.357874
YER 238.496211
ZAR 17.389925
ZMK 9001.196752
ZMW 22.588431
ZWL 321.999592
- Green shines as Suns thump Clippers 115-102
- Japan to screen #MeToo film months after Oscar nomination
- Erasmus relishing 'brutal' France re-match on Paris return
- Rejuvenated Vlahovic taking the reins for Juve ahead of Turin derby
- 'Well-oiled' Leipzig humming along in Bayern's slipstream
- Bangladesh cricket probes sexual harassment claims
- NFL-best Broncos edge Raiders to win seventh in a row
- Deadly Typhoon Kalmaegi ravages Vietnam, Philippines
- Three killed in new US strike on alleged drug boat, toll at 70
- Chinese microdrama creators turn to AI despite job loss concerns
Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
FRAMINGHAM, MA / ACCESS Newswire / February 27, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting being held March 12 - 14, 2025 in San Diego, CA and virtually.
Details for the presentation are as follows:
Abstract Number: 123
Title: DNase I Intervention Enhances CAR-T Cell Therapy in Solid Tumors by Targeting Neutrophil Extracellular Traps in Metastatic Melanoma
Presenter: Alexey Stepanov, PhD, Institute Investigator at The Scripps Research Institute
Date & Time: Wednesday, March 12, 2025 at 5:10 p.m. - 6:45p.m. PT
For more information, please visit the conference website here.
About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.
For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.
Contact:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
[email protected]
SOURCE: Xenetic Biosciences, Inc.
View the original press release on ACCESS Newswire
M.Chau--ThChM
